Application of Britinib in preparation of medicine for treating idiopathic pulmonary fibrosis

Abstract

The invention provides application of Britinib in preparation of a medicine for treating idiopathic pulmonary fibrosis. Britinib has a good effect on idiopathic pulmonary fibrosis, has no adverse reaction, and can improve the forced vital capacity, inspiration airway resistance, expiration airway resistance and dynamic compliance of patients with idiopathic pulmonary fibrosis; the lung collagen content of the patients with idiopathic pulmonary fibrosis is reduced; and the pulmonary fibrosis area is reduced or the increase of the pulmonary fibrosis area is prevented.

Description

Technical field[0001]The present invention has created a biomedical field, and in particular to Brittenib in the preparation of drugs for the treatment of idiopathic pulmonary fibrosis.Background technique[0002]With the exacerbation of environmental pollution, the incidence of pulmonary diseases continued to rise. Pulmonaryfibrosis, PF) is characterized by alveolar continuous injury, fibroblast proliferation, and extension of extracellular matrix (ECM), resulting in different degrees of inflammation and fibrosis in alveolar and pulmonary metals, thereby A disease that causes pulmonary structures and respiratory failure, which is also known as an interStitial lung disease (ILD) or diffuse substantial pulmonary disease (DPLD).[0003]Causes the cause of pulmonary fibrosis, including physical factors, chemical factors, biometric factors, etc., also include unknown pulmonary fibrosis, such as idiopathic pulmonary fibrosis. Idiopathic Pulmonary Fibrosis, IPF) belongs to the idiopathic pneu...

AI Technical Summary

Problems solved by technology

Although these drugs can delay the rate of decline in lung function, they cannot reverse the progression of the disease, and a considerable number of patients respond poorly to treatment, and the specific pharmacological mechanism has not yet been fully elucidated

Images